Campaign

CRO#: 692826

ProVascTec

Cell Therapy / BioTech

EIIS 
A UCC spin-out which developed a novel mechanism for the efficient delivery of cell therapies for the treatment of patients suffering from blocked lower-leg arteries.
by Dr. Holger Mueller
Cork
115% Funded
€ 900,000 Funding goal
€ 1,038,128 Invested
172Investors


Company Summary :

 

 

  • An outstanding, multi-PhD Founding Team
  • A MedTech spin-out from UCC
  • Patent-protected technology (already granted in Europe and the USA)
  • Global market size of $20 billion
  • An Enterprise Ireland High Potential Start-Up company
  • Already received €100,000 from NLC ventures (a Dutch-based venture capital firm)
  • Qualifies for a 50% EIIS Tax Refund for private investors
  • A pre-money Valuation of €5.3m
  • NLC Ventures investing again in this round on the exact same terms as private investors
  • Potential for 30X return on your investment